First-Line Treatment for Asthma in Adults
For adults with persistent asthma, the first-line controller treatment is a low-dose inhaled corticosteroid (ICS), combined with an as-needed short-acting beta-agonist (SABA) for quick relief. 1
Treatment Algorithm by Asthma Severity
Step 1: Intermittent Asthma
- Preferred: As-needed SABA only (e.g., albuterol)
- No daily controller medication needed 1
Step 2: Mild Persistent Asthma (First-Line Controller Therapy)
- Preferred: Daily low-dose ICS + as-needed SABA 1
- Alternative options (if patient unable/unwilling to use ICS):
Critical point: The 2020 GINA update emphasizes that adults should NOT be treated with SABA alone, even for mild asthma, as this increases exacerbation risk 2, 3. The newer approach recommends either daily low-dose ICS plus as-needed SABA, or as-needed concomitant ICS-SABA therapy 4.
Step 3 and Beyond: Moderate-Severe Persistent Asthma
- Preferred: Low-dose ICS + long-acting beta-agonist (LABA), specifically ICS-formoterol as single maintenance and reliever therapy (SMART/MART) 5, 4
- This combination is superior to doubling ICS dose alone 6
Key Clinical Considerations
When to initiate controller therapy:
- Using SABA more than 2 days per week for symptom relief (not counting pre-exercise use) indicates inadequate control and need for controller therapy 1
- Any patient with persistent symptoms requires at least Step 2 treatment
Common pitfalls to avoid:
- Never prescribe SABA monotherapy for persistent asthma - this is outdated and increases mortality risk 2, 3
- Check inhaler technique and adherence before escalating therapy 1, 5
- Assess environmental triggers and comorbidities (GERD, rhinitis, obesity) before stepping up 1
Essential components at every step:
- Patient education on proper inhaler technique 1, 7
- Written asthma action plan 2
- Environmental control measures 1
- Management of comorbidities 1
Monitoring and Adjustment
Reassess control every 2-6 weeks after initiating or changing therapy 5. Once well-controlled for at least 3 consecutive months, consider stepping down by 25-50% 1, 7. If control is inadequate, verify adherence and technique before stepping up treatment 1, 5.
The evidence strongly supports ICS as the cornerstone of asthma therapy - they reduce exacerbations, hospitalizations, and mortality more effectively than any other medication class 8, 9. While leukotriene modifiers offer convenience with once-daily oral dosing and may be equally effective in real-world settings for some patients 8, ICS remain the evidence-based first choice for most adults with persistent asthma.